For radiopharmaceuticals, regulatory approval is only the beginning of value realization.The development of Pluvicto shows that whether a radiopharmaceutical can truly reach patients depends not only ...
A high-quality clinical research network often begins with a leading site that combines access to patients, technical capabilities, and extensive research experience.Consider the team led by Professor...
The momentum behind radiopharmaceuticals is not being driven by a handful of major transactions alone.A field once viewed as niche, complex, and capital-intensive is now being reassessed as a precisio...
Can an investigator-initiated trial (IIT) change the commercial value of an innovative technology?The answer is not a simple yes or no.The more important question is whether an early clinical study ca...
Investigator-initiated clinical research, commonly referred to as IITs, is generally driven by scientific questions arising from clinical practice. As the conduct of IITs becomes increasingly standard...
The real dividing line in CGT research is not simply “completing administration.” It lies in what happens afterward: five years, ten years, and in some cases even lifelong follow-up.It is during thi...
